- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02367638
Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults
April 25, 2017 updated by: Green Cross Corporation
A Single-center, Dose Block-randomized, Single-blind, Active-controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of MG1111 in Healthy Adults
The purpose of this study is to determine whether varicella live vaccine is safe and effective in the healthy adults.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
39
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Healthy male and female individuals between 20 and 55 years of age at screening test
- In the case of female, individuals must be applicable for one of the following;
- In the case of female of childbearing potential, any negative pregnancy test using urine hCG at screening
- Menopausal for at least 2 years
- Surgical sterilization (status after hysterectomy, bilateral oophorectomy, bilateral tubal ligation or the status using other contraceptive methods)
- Monogamous relationship with vasectomized partner prior to screening visit
- Individuals who are used acceptable contraceptive methods from 3 month prior to the subject's study entry to 1 month after vaccination (acceptable contraceptive methods; condom, diaphragm or cervical cap)
- If male who is sexually active with the female "of childbearing potential" , the individuals who agree to use any of the acceptable contraceptive methods during this study period and agree to not donate the sperm until 1 month
- At screening visits, individuals who are over 55 kg in man, over 50kg in woman and whose ideal body weight is within 20 % ((ideal body weight = (height -100)*0.9)
- Individual who has no clinically significant abnormalities in screening test within 28 days prior to vaccination
- Individuals who were voluntarily signed informed consent form after receiving education about this study and able to comply with the requirements for the study
Exclusion Criteria:
- Individuals who received any other vaccines within 4 weeks prior to the screening visit
- Individuals who are planning to receive the other vaccines during this study
- Individuals who had wound, scar, tattoo, dermatological disorders or injection affecting safety evaluation
- Individuals with alcohol or caffeine abuse or heavy smoker (caffeine : >5 cups/day, alcohol : 210g/week, smoke : 10 /day)
- Individuals who received any other investigational product within 90 days prior to vaccination
- individuals who donated the whole blood within 60 days or apheresis within 30 days prior to vaccinating investigational product
- Individuals who administered with another prescription medicine, herbal medicine within 14 days or over-the-counter drug or vitamins within 7 days before vaccination
- Individuals with history or illness affecting immune system (1) individuals with continuously anti-viral therapy within 6 months prior to participating in this study (2) Individuals with leukemia, lymphoma, other malignant neoplasm or hematodyscrasia affecting the bone marrow or lymphatic system (3) Immunodeficient individuals (primary or acquired immunodeficiency states, immunodeficiency, hypogammaglobulinemia, dysgammaglobulinemia) (4) Individuals who are receiving immunosuppressive therapy (5) Individuals who have treated immunoglobulin or blood-derived products within 6 months of enrollment (6) Individuals with a family history of congenital or hereditary immunodeficiency
- Individuals with any clinically relevant history of other disease or disorder - gastrointestinal, respiratory, renal, hepatic, neurological (Guillain-Barre syndrome), psychiatric or malignant tumor
- Individuals with any febrile illness or body temperature ≥38℃ before vaccination
- Individuals known hypersensitivity or allergy to components of investigational product (including gelatin and neomycin)
- Individuals who are any clinically significant abnormality following the investigator's review of the pre-study physical examination, ECG, and clinical laboratory tests
- Pregnancy or breastfeeding
- Any other ineligible condition at the discretion of the investigator that would be ineligible to participate the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: MG1111
|
Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection
|
ACTIVE_COMPARATOR: VARIVAX
|
VARIVAX is administered by subcutaneous injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the solicited adverse events and unsolicited adverse events during 7 days after vaccination
Time Frame: 7 days
|
7 days
|
To evaluate the unsolicited adverse events during 42 days after vaccination
Time Frame: 42 days
|
42 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the efficacy of Geometric mean titer (GMT) and GMT ratio using FAMA assay antibody titer at Day 42
Time Frame: 42 days
|
42 days
|
To evaluate the efficacy of Geometric mean titer (GMT) and GMT ratio using gpELISA antibody titer at Day 42
Time Frame: 42 days
|
42 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2015
Primary Completion (ACTUAL)
July 1, 2015
Study Registration Dates
First Submitted
February 12, 2015
First Submitted That Met QC Criteria
February 12, 2015
First Posted (ESTIMATE)
February 20, 2015
Study Record Updates
Last Update Posted (ACTUAL)
April 27, 2017
Last Update Submitted That Met QC Criteria
April 25, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MG1111_P1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Varicella (Chicken Pox)
-
GlaxoSmithKlineCompletedChickenpox | Chicken-pox Illness (Varicella Virus Disease)Estonia, Thailand, Germany, Mexico, United Kingdom
-
Emory UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
USDA, Western Human Nutrition Research CenterCompletedBioavailability of Vitamin B12 From Chicken EggsUnited States
-
Taipei Medical University Shuang Ho HospitalUnknownImmunity | Cognition | Metabolism | Stress Associated Cognitive Inhibition | Essence of ChickenTaiwan
-
Children's Hospital of Fudan UniversityPeople's Hospital of Xinjiang Uygur Autonomous Region; Hainan women and children... and other collaboratorsCompletedPOX Range of Healthy Newborns at Different Altitudes | POX Threshold for Screening Major CHD in NeonatesChina
-
Beni-Suef UniversityCompleted
-
The HIV Netherlands Australia Thailand Research...Chulalongkorn UniversityCompletedHIV Infections | Varicella-zoster VirusThailand
-
PENTA FoundationUniversity College, London; European Commission; Servicio Madrileño de Salud,... and other collaboratorsRecruiting
-
Institute of Tropical Medicine, BelgiumCompleted
-
Institut PasteurCentre Médical de l'Institut PasteurRecruiting
Clinical Trials on MG1111
-
Green Cross CorporationRecruiting
-
GC Biopharma CorpNot yet recruitingVaricella Zoster Virus Infection